- Home
- CYCN vs SLXN Comparison
CYCN vs SLXN Comparison
Compare CYCN & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- SLXN
- Stock Information
- Founded
- CYCN 2018
- SLXN 2008
- Country
- CYCN United States
- SLXN Israel
- Employees
- CYCN N/A
- SLXN N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- CYCN Health Care
- SLXN
- Exchange
- CYCN Nasdaq
- SLXN NYSE
- Market Cap
- CYCN 8.4M
- SLXN 5.0M
- IPO Year
- CYCN N/A
- SLXN N/A
- Fundamental
- Price
- CYCN $4.12
- SLXN $1.36
- Analyst Decision
- CYCN
- SLXN Strong Buy
- Analyst Count
- CYCN 0
- SLXN 1
- Target Price
- CYCN N/A
- SLXN $9.00
- AVG Volume (30 Days)
- CYCN 5.8M
- SLXN 32.1M
- Earning Date
- CYCN 03-04-2025
- SLXN 02-21-2025
- Dividend Yield
- CYCN N/A
- SLXN N/A
- EPS Growth
- CYCN N/A
- SLXN N/A
- EPS
- CYCN N/A
- SLXN N/A
- Revenue
- CYCN $194,000.00
- SLXN N/A
- Revenue This Year
- CYCN N/A
- SLXN N/A
- Revenue Next Year
- CYCN N/A
- SLXN N/A
- P/E Ratio
- CYCN N/A
- SLXN N/A
- Revenue Growth
- CYCN N/A
- SLXN N/A
- 52 Week Low
- CYCN $1.27
- SLXN $0.21
- 52 Week High
- CYCN $9.47
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- CYCN 56.08
- SLXN N/A
- Support Level
- CYCN $2.81
- SLXN N/A
- Resistance Level
- CYCN $4.80
- SLXN N/A
- Average True Range (ATR)
- CYCN 0.68
- SLXN 0.00
- MACD
- CYCN 0.13
- SLXN 0.00
- Stochastic Oscillator
- CYCN 43.54
- SLXN 0.00
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.